chartexchange

Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update

GlobeNewswire Inc. | Nov 12, 2026 6:00 AM EST

SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

Read original article